Dicot Pharma (DICOT) Investor Update summary

TO 6 warrant update

• TO 6 warrants exercisable March 17–31, 2025; Q&A scheduled via Zoom on March 20 at 12:30, in Swedish, with a recording available afterward.

• CEO Elin Trampe said the session would begin with a short status update, followed by questions from existing and potential warrant holders.

• Questions could be submitted during the session or in advance; information on subscription and use of proceeds was sent to warrant and share holders registered in Sweden.

Development overview

• LIB-01 is being developed as a treatment candidate for erectile dysfunction and premature ejaculation, with the aim of longer-lasting effects and fewer side effects than current drugs.

• The stated market context was over 500 million men affected and a market valued at USD 8 billion; partnership evaluation is planned during clinical development.